Abstract: Disclosed are replication-enhanced oncolytic adenoviruses. These oncolytic adenoviruses have tumor-specific replication capable of enhanced tumor oncolysis and enhanced therapeutic transgene expression. Also disclosed are methods comprising administering a replication-enhanced oncolytic adenovirus for patients suffering from a cancer.

Abstract: Disclosed are and methods for expanding tumor infiltrating lymphocyte (TIL) populations and methods of the use of the expanded TIL population for treating cancer. In one aspect, disclosed herein are methods of generating tumor infiltrating lymphocytes comprising a) administering an effective amount of an oncolytic virus expressing one or more exogenous immunostimulatory molecules (such as, for example, CD40-L, MEM40, B7-1(CD80)/B7-2(CD86), OX40L, 4-1BBL, CD70, GITRL, LIGHT, TIM-4, ICAM-1, CD58 and/or SLAMF6) into a tumor cell; and b) harvesting the tumor infiltrating lymphocytes. In some aspects, the oncolytic virus can further express one or more type 1 interferon (IFN)(such as, for example, IFN-?, IFN-?, IFN-?, IFN-?, IFN-?, IFN-?, IFN-?, and/or IFN-?). In some aspects, the TILs generated are obtained in the tumor microenvironment at the site of the administration of the oncolytic virus; however TILs can also be obtained at tumor microenvironments not infected with the oncolytic virus.

Abstract: Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one immune checkpoint inhibitor and a chimeric CD 154 polypeptide. Also provided herein are methods of enhanced immune function.

Abstract: The present disclosure provides methods and compositions for enhancing immunity by administering a coronavirus vaccine and a chimeric CD40L polypeptide. The coronavirus vaccine can be comprised of inactivated coronaviral particles or an antigenic polypeptide, preferably the coronavirus spike protein. The coronavirus antigenic polypeptide can be a purified antigenic polypeptide or a nucleic acid expression construct that encodes the antigenic polypeptide. The chimeric CD40L polypeptide in compositions of the invention can be a purified chimeric CD40L polypeptide or a nucleic acid expression construction that encodes the chimeric CD40L polypeptide.

Abstract: Disclosed are replication-enhanced oncolytic adenoviruses. These oncolytic adenoviruses have tumor-specific replication capable of enhanced tumor oncolysis and enhanced therapeutic transgene expression. Also disclosed are methods comprising administering a replication-enhanced oncolytic adenovirus for patients suffering from a cancer.